This page lists the SEC filings reported by Nussbaum Ran.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2022-02-14 | Nussbaum Ran | PIERIS PHARMACEUTICALS, INC. | 3,571,428 | 5.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Nussbaum Ran | 89bio, Inc. | 827,701 | 4.1% | EDGAR |
| SC 13G/A | 2021-02-16 | Nussbaum Ran | LogicBio Therapeutics, Inc. | 1,499,053 | 4.7% | EDGAR |
| SC 13G | 2021-02-16 | Nussbaum Ran | PIERIS PHARMACEUTICALS, INC. | 3,571,428 | 6.4% | EDGAR |
| SC 13G/A | 2021-02-11 | Nussbaum Ran | LogicBio Therapeutics, Inc. | 1,629,053 | 5.1% | EDGAR |
| SC 13G/A | 2021-02-09 | Nussbaum Ran | 89bio, Inc. | 1,022,454 | 5.1% | EDGAR |
| SC 13G/A | 2021-02-05 | Nussbaum Ran | PURPLE BIOTECH LTD. | 80,753 | 0.5% | EDGAR |
| SC 13G/A | 2020-02-14 | Nussbaum Ran | Enlivex Therapeutics Ltd. | 46,753 | 0.5% | EDGAR |
| SC 13G | 2020-02-14 | Nussbaum Ran | LogicBio Therapeutics, Inc. | 1,787,413 | 7.7% | EDGAR |
| SC 13G | 2020-02-14 | Nussbaum Ran | 89bio, Inc. | 1,134,671 | 8.2% | EDGAR |
| SC 13G | 2020-02-13 | Nussbaum Ran | Kitov Pharma Ltd. | 1,560,566 | 5.1% | EDGAR |
| SC 13G/A | 2020-01-21 | Nussbaum Ran | Entera Bio Ltd. | 120,250 | 0.7% | EDGAR |
| SC 13G/A | 2019-02-14 | Nussbaum Ran | Bioblast Pharma Ltd. | 344,820 | 10.2% | EDGAR |
| SC 13G | 2019-02-14 | Nussbaum Ran | Entera Bio Ltd. | 420,940 | 3.6% | EDGAR |
| SC 13G/A | 2018-02-14 | Nussbaum Ran | Bioblast Pharma Ltd. | 508,052 | 15.2% | EDGAR |
| SC 13G | 2017-05-25 | Nussbaum Ran | Novus Therapeutics, Inc. | 536,759 | 7.7% | EDGAR |
| SC 13G | 2015-02-17 | Nussbaum Ran | BIO BLAST PHARMA LTD. | 2,529,008 | 17.8% | EDGAR |
| SC 13G | 2015-02-12 | Nussbaum Ran | Kite Pharma, Inc. | 2,251,936 | 5.1% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.